Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease

Pediatric Nephrology

Volumn 26, Issue 7, 2011, Pages 1105-1114

  Siomou, Ekaterini ^a   Challa, Anna ^a   Printza, Nikoleta ^b   Giapros, Vasileios ^a   Petropoulou, Fotini ^c   Mitsioni, Andromachi ^c   Papachristou, Fotios ^b   Stefanidis, Constantinos J ^c  

^a UNIVERSITY OF IOANNINA   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c P AND A KYRIAKOU CHILDREN S HOSPITAL   (Greece)

Author keywords

Biochemical markers of bone turnover; Chronic kidney disease; FGF 23; OPG; RANKL; Renal osteodystrophy

Indexed keywords

25 HYDROXYVITAMIN D; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALFACALCIDOL; ALKALINE PHOSPHATASE; CALCIUM; CALCIUM CARBONATE; CARBOXY TERMINAL TELOPEPTIDE; FIBROBLAST GROWTH FACTOR 23; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHATE; SODIUM CARBONATE; TARTRATE RESISTANT ACID PHOSPHATASE 5B; UNCLASSIFIED DRUG;

AGE; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BODY MASS; BONE TURNOVER; CALCIUM BLOOD LEVEL; CHILD; CHILDHOOD DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHOOL CHILD; VITAMIN BLOOD LEVEL;

ACID PHOSPHATASE; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BONE REMODELING; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; FEMALE; FIBROBLAST GROWTH FACTORS; GREECE; HUMANS; ISOENZYMES; KIDNEY DISEASES; MALE; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHATES; RANK LIGAND; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX;

EID: 80052478693     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-011-1870-5     Document Type: Article

References (37)

1. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69:1945-1953. (Pubitemid 43924257)
2. Salusky IB, Coburn JW, Brill J, Foley J, Slatopolsky E, Fine RN, Goodman WG (1988) Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney Int 33:975-982.
3. Salusky IB, Ramirez JA, Oppenheim W, Gales B, Segre GV, Goodman WG (1994) Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int 45:253-258. (Pubitemid 24046016)
4. Ziólkowska H, Pańczyk-Tomaszewska M, Debiński A, Polowiec Z, Sawicki A, Sieniawska M (2000) Bone biopsy results and serum bone turnover parameters in uremic children. Acta Paediatr 89:666-671. (Pubitemid 30624909)
5. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, Wolf M (2005) Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16:2205-2215. (Pubitemid 41716454)
6. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319. (Pubitemid 27199902)
7. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS (2000) Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192:463-474. (Pubitemid 30666247)
8. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a lignad for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANE/RANKL. Proc Natl Acad Sci USA 95:3597-3602.
9. Li X, Ominsky MS, Stolina M, Warmington KS, Geng Z, Niu QT, Asuncion FJ, Tan HL, Grisanti M, Dwyer D, Adamu S, Ke HZ, Simonet WS, Kostenuik PJ (2009) Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor ostoprotegerin. Bone 45:669-676.
10. Huang JC, Sakata T, Pfieger LL, Bencsik M, Halloran BP, Bikle DD, Nissenson RA (2004) PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res 19:235-244. (Pubitemid 38116737)
11. Coen G, Ballanti P, Balducci A, Calabria S, Fischer MS, Jankovic L, Manni M, Morosetti M, Moscaritolo E, Sardella D, Bonucci E (2002) Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant 17:233-238. (Pubitemid 34157136)
12. Shaarawy M, Fathy SA, Mehany NL, Hindy OW (2007) Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure. Clin Chem Lab Med 45:1498-1503. (Pubitemid 350041615)
13. Ziólkowska H, Roszkowska-Blaim M (2006) Osteoprotegerin and calcium-phosphorus metabolism parameters in children with chronic renal failure. Przegl Lek 63[Suppl 3]:68-71.
14. Swolin-Eide D, Hansson S, Larsson L, Magnusson P (2006) The novel bone alkaline phosphatase B1x isoform in children with kidney disease. Pediatr Nephrol 21:1723-1729. (Pubitemid 44399119)
15. Swolin-Eide D, Magnusson P, Hansson S (2007) Bone mass, biochemical markers and growth in children with chronic kidney disease: a 1-year prospective study. Acta Paediatr 96:720-725. (Pubitemid 46653172)
16. Swolin-Eide D, Hansson S, Magnusson P (2009) Children with chronic kidney disease: a 3-year prospective study of growth, bone mass and bone turnover. Acta Paediatr 98:367-373.
17. Shroff RC, Shah V, Hiorns MP, Schoppet M, Hofbauer LC, Hawa G, Schurgers LJ, Singhal A, Merryweather I, Brogan P, Shanahan C, Deanfield J, Rees L (2008) The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not Matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol Dial Transplant 23:3263- 3271.
18. Ozkaya O, Buyan N, Bideci A, Gonen S, Ortac E, Fidan K, Cinaz P, Söylemezoǧlu O (2007) Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis. Nephron Clin Pract 105: c153-c158. (Pubitemid 46492430)
19. Kagami S, Ohkido I, Yokoyama K, Shigematsu T, Hosoya T (2008) Osteoprotegerin affects the responsiveness of fibroblast growth factor-23 to high oral phosphate intake. Clin Nephrol 70:306-311.
20. Kidney Disease Outcomes Quality Initiative, National Kidney Foundation (2005) K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 46[4 Suppl 1]:S1-S121.
21. Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629-637.
22. Klaus G, Watson A, Edefonti A, Fischbach M, Rönnholm K, Schaefer F, Simkova E, Stefanidis CJ, Strazdins V, Vande Walle J, Schröder C, Zurowska A, Ekim M, European Pediatric Dialysis Working Group (EPDWG) (2006) Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr Nephrol 21:151-159. (Pubitemid 43115864)
23. Wesseling-Perry K (2010) FGF-23 in bone biology. Pediatr Nephrol 25:603-608.
24. Kazama JJ, Kato H, Sato T, Shigematsu T, Fukagawa M, Iwasaki Y, Gejyo F (2002) Circulating osteoprotegerin is not removed through haemodialysis membrane. Nephrol Dial Transplant 17:1860-1861. (Pubitemid 35174314)
25. Wittersheim E, Mesquita M, Demulder A, Guns M, Louis O, Melot C, Dratwa M, Bergmann P (2006) OPG, RANK-L, bone metabolism, and BMD in patients on peritoneal dialysis and hemodialysis. Clin Biochem 39:617-622. (Pubitemid 43949099)
26. Wesseling K, Bakkalogly S, Salusky I (2008) Chronic kidney disease mineral and bone disorder in children. Pediatr Nephrol 23:195-207.
27. Rogers A, Eastell R (2005) Review: Circulating osteoprotegerin and receptor activator for nuclear factor κB ligand: Clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 90:6323-6331. (Pubitemid 41606564)
28. Kuro-o M (2010) Overview of the FGF23-Klotho axis. Pediatr Nephrol 25:583-590.
29. Gattineni J, Baum M (2010) Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism. Pediatr Nephrol 25:591-601.
30. Krajisnik T, Björklund P, Marsell R, Ljunggren O, Akerström G, Jonsson KB, Westin G, Larsson TE (2007) Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 195:125-131. (Pubitemid 350056006)
31. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Naveh-Many T, Silver J (2007) The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117:4003-4008. (Pubitemid 350224109)
32. Hasegawa H, Nagano N, Urakawa I, Yamazaki Y, Iijima K, Fujita T, Yamashita T, Fukumoto S, Shimada T (2010) Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 78:975-980.
33. Magnusson P, Hansson S, Swolin-Eide D (2010) A prospective study of fibroblast growth factor-23 in children with chronic kidney disease. Scand J Clin Lab Invest 70:15-20.
34. Wesseling-Perry K, Pereira RC, Wang H, Elashoff RM, Sahney S, Gales B, Jüppner H, Salusky IB (2009) Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 94:511-517.
35. Ureña P, De Vernejoul MC (1999) Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 55:2141-2156. (Pubitemid 29256470)
36. Shidara K, Inaba M, Okuno S, Yamada S, Kumeda Y, Imanishi Y, Yamakawa T, Ishimura E, Nishizawa Y (2008) Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients. Calcif Tissue Int 82:278-287.
37. Seiler S, Heine GH, Fliser D (2009) Clinical relevance of FGF-23 in chronic kidney disease. Kidney Int 76[Suppl 114]:S34-S42.